RBC Capital analyst Sean Dodge maintained a Buy rating on Teladoc (TDOC – Research Report) on January 31 and set a price target of $35.00. The company’s shares closed yesterday at $30.74.
According to TipRanks, Dodge is an analyst with an average return of -2.2% and a 46.58% success rate. Dodge covers the Technology sector, focusing on stocks such as Tabula Rasa HealthCare, Allscripts, and NextGen Healthcare.
Currently, the analyst consensus on Teladoc is a Hold with an average price target of $32.45, representing a 5.56% upside. In a report released on January 19, Oppenheimer also maintained a Buy rating on the stock with a $37.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $79.90 and a one-year low of $21.60. Currently, Teladoc has an average volume of 4.34M.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TDOC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teladoc Health, Inc. is a multinational telemedicine and virtual healthcare company. The company provides telehealth solutions, expert medical services, medical opinions, artificial intelligence and analytics, behavioral health solutions, guidance and support, and platform and program services.
Read More on TDOC:
- Teladoc Health to Announce Fourth Quarter 2022 Financial Results
- Teladoc call volume above normal and directionally bullish
- Cathie Wood Gets Back on Track; Here Are 2 Stocks She’s Snapping Up
- Teladoc Health Releases Annual Corporate Social Responsibility Report
- Sell these stocks now, proven algorithm says
